NEW YORK (Reuters Health) – Ovarian suppression, using a luteinizing hormone-releasing hormone agonist, during neoadjuvant chemotherapy for breast cancer in premenopausal women does not help preserve subsequent ovarian function, a German team reports.
Writing in the Journal of Clinical Oncology online May...
Teresa L. Knight, MD, FACOG, Chief Medical Officer of the Women’s Health Specialists of Saint Louis, discusses the risks of inherited breast cancer gene mutations.
To learn more about the Women’s Health Specialists of Saint Louis, please...
NEW YORK (Reuters Health) – Long-term results confirm that use of neoadjuvant chemotherapy in treating muscle-invasive cancer of the bladder confers a significant survival advantage, an international collaborative group reports in the Journal of Clinical Oncology online April 18.
Between 1989 and 1995, 976...